Antiangiogenic Therapy Combined with Chemotherapy Including Platinum Agents as a Therapeutic Option for Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options. While rationally-derived regimens are emerging from the results of recent gene profiling studies, TNBC is an angiogenesis-dependent malignancy, and antiangiogenic therapies have been examined energetically in this field. Antiangiogenic agents in combination with chemotherapeutic platinum compounds have shown some benefit in recent randomized control studies for the treatment of TNBC. These combinations could be more safe and efficacious in patients, when pharmacotherapy schedule is modified taking into account its tolerability.